Source: ERJ Open Res, 5 (4) 00182-2019; 10.1183/23120541.00182-2019
Disease area: Airway diseases, Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Kameshwar P. Singh, Gina Lawyer, Thivanka Muthumalage, Krishna P. Maremanda, Naushad Ahmad Khan, Samantha R. McDonough, Dongxia Ye, Scott McIntosh, Irfan Rahman. Systemic biomarkers in electronic cigarette users: implications for noninvasive assessment of vaping-associated pulmonary injuries. ERJ Open Res, 5 (4) 00182-2019; 10.1183/23120541.00182-2019

Member's Comments

No comment yet.

Related content which might interest you: Noninvasive assessment in the evaluation of occupational lung diseases Source: Annual Congress 2009 - MP8 - Noninvasive assessment in the evaluation of occupational lung diseases Year: 2009 Risk stratification of pulmonary embolism: clinical evaluation, biomarkers or both? Source: Eur Respir J 2015; 46: 1551-1553 Year: 2015 Are FENO indices useful diagnostic tools in suspected asthma? Experience of a routine lung function laboratory Source: Annual Congress 2011 - Bronchial hyperresponsiveness and exhaled and sputum biomarkers Year: 2011 Evaluation of recently validated non-invasive formula using basic lung functions as a new screening tool for pulmonary hypertension in patients with idiopathic pulmonary fibrosis Source: Annual Congress 2009 - Pulmonary vascular diseases Year: 2009 Smoking cessation: a critical investigative tool in COPD Source: Eur Respir J 2006; 27: 860-861 Year: 2006 Current clinical management of smoke inhalation injuries: a reality check Source: Eur Respir J, 52 (6) 1802163; 10.1183/13993003.02163-2018 Year: 2018 Measuring inflammation inpaediatric severe asthma: biomarkers in clinical practice Source: Breathe, 16 (1) 190301; 10.1183/20734735.0301-2019 Year: 2020 Assessing the effect of medical therapy in COPD: from pathophysiology and biomarkers to clinical practice Source: Annual Congress 2009 - PG15 The complexity of COPD: assessment and advanced therapies Year: 2009 Distance assessment of the risk of pulmonary hypertension associated with connective tissue diseases: do biomarkers help? Source: Virtual Congress 2021 – Pulmonary hypertension in the COVID-19 pandemic and beyond Year: 2021 New potential diagnostic biomarkers for pulmonary hypertension Source: Eur Respir J 2015; 46: 1390-1396 Year: 2015 Serial FEV1 measurements: an improved diagnostic tool for occupational asthma? Source: International Congress 2017 – Asthma: clinical and epidemiologic characterisation Year: 2017 The clinical role of routine non-invasive parameters in the diagnostic work-up of patients with risk for pulmonary hypertension Source: Annual Congress 2012 - Pulmonary circulation: clinical diagnosis, treatment, end-points and animal models Year: 2012 Pulmonary hypertension and COPD: Clinical assessment and biomarkers Source: Annual Congress 2013 –Pulmonary circulation: clinical pulmonary hypertension II Year: 2013 Screening pulmonary hypertension by lung doppler signal: A proof-of-concept study Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights Year: 2015 Is it time for home treatment of pulmonary embolism Source: Eur Respir J 2012; 40: 742-749 Year: 2012 Clinical applications of electronic monitoring - potential and pitfalls Source: Annual Congress 2005 - Practical and scientific considerations in the use of new electronic technologies for ambulatory monitoring of respiratory disease Year: 2005 Role of biomarkers in the assessment and phenotyping asthma and COPD Source: ERS Skills course - Biomarkers and functional assessment of obstructive lung diseases Year: 2017 Comparison of risk assessment strategies for not-high-risk pulmonary embolism Source: Eur Respir J 2016; 47: 1170-1178 Year: 2016 Gamma-Glutamyltransferase in pulmonary hypertension: A reliable biomarker? Source: Virtual Congress 2020 – Clinical evaluation, biomarkers and risk assessment of pulmonary hypertension Year: 2020